Introduction: National Institute for Health and Care Excellence (NICE) guidelines on the assessment and management of psoriasis recommend annual screening for psoriatic arthritis in all patients with psoriasis. Validated assessment tools are available for screening in adults; however no validated tools are recommended for juvenile psoriatic arthritis. Aim: This study aimed to understand dermatologists' routine practice and the difficulties they experience when assessing children for juvenile psoriatic arthritis. Methods: Structured telephone interviews were undertaken with dermatologists identified through the British Society of Paediatric Dermatology. Percentages for binary and categorised responses were calculated and an average Likert scale response. Thematic content analysis was used to identify common themes across the interviews. Results: 23 of the 41 consultant dermatologists contacted agreed to be interviewed; each representing a different UK centre. 18/23 (78%) of dermatologists reported that they routinely ask about joint disease, which always involved asking about symptoms, most commonly pain. Only 3/23 (13%) reported they routinely examine the joints of children with psoriasis. The average confidence rating for assessing joint disease in children was low at 3 on a scale of 1 to 10. The two dominant subthemes were a lack of confidence and uncertainty. The two key barriers reported for detecting arthritis were lack of experience/training and that physical signs in arthritis may be subtle or difficult to detect. The two key suggestions for improving detection were using an assessment tool/ guideline and increased clinical experience/training. Conclusion: It would be helpful for dermatologists to use a standardised and effective approach when screening for juvenile psoriatic arthritis. Measures to increase dermatologists' confidence in paediatric musculoskeletal examination and the evaluation and implementation of a screening tool, such as pGALS, should be considered.
NATIONAL SURVEY OF ADMINISTRATION OF LIVE-VACCINES TO CHILDREN ON METHOTREXATE OR BIOLOGIC THERAPIES FOR JIA
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Background: Varicella, measles and flu remain major concerns for public health, clinicians and parents. Non-immunity and the risk of contact cause anxiety, lost schooling, interruption of immunomodulation, expensive intervention and potential morbidity. These risks may be mitigated by vaccination. Non-live vaccines are considered safe in patients on DMARDs/biologic agents, but national guidelines 3 recommend withholding live-vaccines. Since Davies and Woo 2 survey of confidence to immunize found 13% services gave live vaccines in this population, a body of evidence has built up to question this orthodoxy 4 Aims: Test whether recent evidence of safety and efficacy of livevaccine use has been associated with change in practice across the UK; explore the gap between national guidelines and practice and identify whether there is scope to standardise practice. Methods: Survey design, with a questionnaire, supported by the topic specific research group and circulated via BSPAR for doctors and nurses to complete. Results: 38 completed responses from 19 consultants (all paediatric), 17 nurses, 1 junior doctor and 1-pharmacist from >20 hospitals (13/15 tertiary centres; 5 respondents withheld location Background: Juvenile idiopathic arthritis (JIA) is a disease with an age of onset before 16, characterized by the presence of persistent arthritis in one or more joints, for at least six weeks, given that other causes have been ruled out. JIA diagnosis is based mainly on clinical history and physical examination. 1 There are very limited serological markers with valid serological value. An autoantibody called anti-cyclic citrullinated peptide (anti-CCP) has been studied. The frequency of autoantibodies in adults were well investigated, but limitedly studied in JIA.
2 Aims: The purpose of present study was to access the prevalence of anti-CCP antibodies in children with JIA, and to investigate the clinical significance and diagnostic value of the anti-CCP antibodies in correlation with age, sex and activity. Methods: This case-control study was performed on 50 patients with JIA in addition to a control group of 40 sex and age-matched children. The participants were recruited from rheumatology Clinic of Cairo University Paediatric Hospital. Patients were subjected to clinical examination, routine laboratory investigations and x-rays on involved joints. Both patients and controls underwent assay of anti-CCP antibodies by AxSYM Anti-CCP IgG Microparticle Enzyme Immunoassay (MEIA). Data were analyzed using Mann-Whitney U test, ANOVA, and independent-samples t-test. Results: Anti-CCP positivity was detected among patients with JIA, especially those JIA patients with RF positive polyarticular disease onset. Most importantly is that anti-CCP positivity was significantly correlated with bone erosions, degree of joint damage, and ESR levels. Conclusions: Anti-CCP could serve as a useful marker in the polyarticular form of JIA to direct early and may be aggressive therapeutic intervention. 
